Eli Lilly stock soars on earnings, 'off-the-charts' demand for weight-loss drugs
Shares of Eli Lilly (LLY) are soaring in Tuesday's trading session after the company raised its full-year guidance, driven by the surging demand for its offerings. BMO Capital Markets BioPharma Equity Research Managing Director Evan Seigerman joins the Morning Brief to discuss the stock's outlook.
Seigerman notes that "demand is off the charts" for the company, and the raised guidance supports the bullish outlook. Despite missing on revenue, the company beat profit expectations, bolstering Seigerman's optimism about the stock's future performance.
Addressing the competitive landscape Seigerman says it's "unlikely that any competitors are going to be out there in the next couple of years." Even if competitors enter the market, he believes Eli Lilly will continue advancing, giving them a distinct advantage.
Seigerman highlights that the company is becoming "more and more efficient," opening additional facilities to support the surging demand. However, he notes that demand is through the roof, making it challenging to keep up. The analyst adds that his price target for the company is $900, but the stock's performance will be "driven by how quickly they can ramp up supply because the demand is there."
#youtube #news #stockmarket
About Yahoo Finance:
Yahoo Finance provides free stock ticker data, up-to-date news, portfolio management resources, comprehensive market data, advanced tools, and more information to help you manage your financial life.
- Get the latest news and data at finance.yahoo.com
- Download the Yahoo Finance app on Apple (https://apple.co/3Rten0R) or Android (https://bit.ly/3t8UnXO)
- Follow Yahoo Finance on social:
X: http://twitter.com/YahooFinance
Instagram: https://www.instagram.com/yahoofinance/?hl=en
TikTok: https://www.tiktok.com/@yahoofinance?lang=en
Facebook: https://www.facebook.com/yahoofinance/
LinkedIn: https://www.linkedin.com/company/yahoo-finance
Видео Eli Lilly stock soars on earnings, 'off-the-charts' demand for weight-loss drugs канала Yahoo Finance
Seigerman notes that "demand is off the charts" for the company, and the raised guidance supports the bullish outlook. Despite missing on revenue, the company beat profit expectations, bolstering Seigerman's optimism about the stock's future performance.
Addressing the competitive landscape Seigerman says it's "unlikely that any competitors are going to be out there in the next couple of years." Even if competitors enter the market, he believes Eli Lilly will continue advancing, giving them a distinct advantage.
Seigerman highlights that the company is becoming "more and more efficient," opening additional facilities to support the surging demand. However, he notes that demand is through the roof, making it challenging to keep up. The analyst adds that his price target for the company is $900, but the stock's performance will be "driven by how quickly they can ramp up supply because the demand is there."
#youtube #news #stockmarket
About Yahoo Finance:
Yahoo Finance provides free stock ticker data, up-to-date news, portfolio management resources, comprehensive market data, advanced tools, and more information to help you manage your financial life.
- Get the latest news and data at finance.yahoo.com
- Download the Yahoo Finance app on Apple (https://apple.co/3Rten0R) or Android (https://bit.ly/3t8UnXO)
- Follow Yahoo Finance on social:
X: http://twitter.com/YahooFinance
Instagram: https://www.instagram.com/yahoofinance/?hl=en
TikTok: https://www.tiktok.com/@yahoofinance?lang=en
Facebook: https://www.facebook.com/yahoofinance/
LinkedIn: https://www.linkedin.com/company/yahoo-finance
Видео Eli Lilly stock soars on earnings, 'off-the-charts' demand for weight-loss drugs канала Yahoo Finance
Показать
Комментарии отсутствуют
Информация о видео
Другие видео канала
Stocks pull back from records after Dow touches 40,000 for first time | May 16 Yahoo FinanceHow families are affording childcare on a budgetChina unveils plans to revitalize its property marketBooking Holdings versus Disney: Why only one is a buyAmazon and Roku look to cut jobs, Russia-Ukraine grain deal extended, Starbucks workers go on strikeJPMorgan's Jamie Dimon teases retirement and succession planNvidia is the 'poster child for the AI boom,' Schwab's Sonders saysAlabama Mercedes-Benz workers reject UAW bidHomebuilder confidence falls amid high mortgage ratesThese stocks do well in inflationary environmentsASML and TSMC can disable chip machines remotely if China invades Taiwan5 tips to make home-buying easier: BofAWalmart stock pops as Q1 e-commerce sales jump 22%Meta slapped with EU investigation into child safety protocolHow Qualcomm is cementing its spot in the AI raceMacy's Q1 earnings tops estimates, but needs to generate more sales growth analyst saysPriceline CEO talks summer travel, deals, plus hotel and airline pricingTikTok ‘has become incredibly politically toxic to Washington,’ advisor saysGameStop hearing: Keith Gill aka Roaring Kitty opening statement before Capitol Hill lawmakersAre older Americans ready for retirement?What April's CPI data could mean for Fed rate cuts, plus opportunities for investors